Incretin Atlas › Trials › ESSENCE (part 1)
ESSENCE (part 1)
Semaglutide · MASH F2–F3
Design
- Molecule(s)
- Semaglutide
- Population
- MASH F2–F3
- Participants
- 800
- Duration
- 72 weeks
Outcomes in the indication
ESSENCE (part 1) Semaglutide · MASH F2–F3 · 72 weeks · n = 800 seed
Steatohepatitis resolution 62.9 % vs 34.3 %; fibrosis improvement 36.8 % vs 22.4 %; FDA accelerated approval 2025
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis week 72 | +36.8 | +22.4 | +14.4 (+7.5 to +21.3) percentage points | verified |
| Resolution of steatohepatitis without worsening of fibrosis week 72 | +62.9 | +34.3 | +28.7 (+21.1 to +36.2) percentage points | verified |
Verbatim quotes (2)
- Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001)
- Resolution of steatohepatitis without worsening of fibrosis
Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: ESSENCE (part 1). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/essence/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.